The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans
Abstract
We describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ1–42), t‐tau, and p‐tau181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD disease heterogeneity; progress in standardization; and new studies using ADNI biofluids.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 01, 2015
- Source ID
- 10.1016/j.jalz.2015.05.003
Entities
People
- Andrew J. Saykin
- Henrik Zetterberg
- Holly Soares
- Hugo Vanderstichele
- John Q. Trojanowski
- Jon B. Toledo
- Ju‐hee Kang
- Kaj Blennow
- Leona Fields
- Leslie M. Shaw
- Magdalena Brylska
- Magdalena Korecka
- Michael W. Weiner
- Michal J. Figurski
- Nirali Shah
- Paul S. Aisen
- Robert A. Dean
- Ronald C. Petersen
- Teresa Waligorska
- The Alzheimer’s Disease Neuroimaging Initiative*
Organizations
- Alzheimer's Disease Neuroimaging Initiative
- Bristol-Myers Squibb
- Eli Lilly and Company
- Indiana University
- Indiana University School of Medicine
- Inha University
- Mayo Clinic
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- National Research Foundation
- Sahlgrenska University Hospital
- United States Department of Defense
- United States Department of Veterans Affairs
- University College London
- University of California, San Diego
- University of Pennsylvania